Abbott Laboratories (ABT) director reports 62 stock equivalent units in Form 4

Rhea-AI Filing Summary

Abbott Laboratories director reports stock-based board fees. Director Robert J. Alpern acquired 62 stock equivalent units on 12/31/2025 as reported derivative securities tied to Abbott common shares. The units were credited at a reference price of $125.29 per underlying share and are held in a stock equivalent unit account established by the director.

After this transaction, Alpern beneficially owns 10,409 derivative securities representing stock equivalent units, held directly. These director fees are generally paid in cash at about age 65 or upon retirement from the board, and the units are designed to earn the same return as if the fees were invested in Abbott shares, including additional units from a dividend reinvestment feature.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alpern Robert J

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	(1)	12/31/2025		A		62		(1)	(1)	Common Shares	62	$125.29	10,409(2)	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ Robert J. Alpern by Jessica H. Paik, Attorney-in-Fact	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abbott Laboratories (ABT) report in this Form 4?

Director Robert J. Alpern reported acquiring 62 stock equivalent units linked to Abbott Laboratories common shares as of 12/31/2025, recorded as derivative securities held directly.

What are the stock equivalent units reported for Abbott Laboratories (ABT)?

The filing describes stock equivalent units as director fees credited to a stock equivalent unit account under a grantor trust. The units earn the same return as if the fees were invested in Abbott shares, and are generally paid out in cash.

How many Abbott Laboratories stock equivalent units does the director own after this transaction?

Following the reported transaction, Director Robert J. Alpern beneficially owns 10,409 stock equivalent units as derivative securities, held in a direct ownership form.

At what reference price were the new Abbott Laboratories stock equivalent units credited?

The 62 newly acquired stock equivalent units were tied to Abbott common shares at a reference price of $125.29 per underlying share, as disclosed in the derivative securities table.

When are Abbott Laboratories director stock equivalent units generally paid out?

The filing notes that director fees credited as stock equivalent units are paid, in cash, generally at about age 65 or upon the director’s retirement from the board.

How do dividend reinvestments affect the director’s Abbott Laboratories stock equivalent units balance?

The balance of 10,409 stock equivalent units includes units acquired through a dividend reinvestment feature, which adds additional units as dividends are credited.